Clinical Trial Update: Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of MPC-6827 with temozolomide for metastatic melanoma has completed its evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MPC-6827
• Temozolomide (Temozolomide)

Snippet

Sponsor: Myrexis Inc. | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED